We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings
Read MoreHide Full Article
Wall Street analysts expect Agilent Technologies (A - Free Report) to post quarterly earnings of $1.25 per share in its upcoming report, which indicates a year-over-year decline of 12.6%. Revenues are expected to be $1.56 billion, down 6.6% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Agilent metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Revenue by End Markets- Pharmaceutical' will reach $540.08 million. The estimate suggests a change of -8.8% year over year.
The collective assessment of analysts points to an estimated 'Revenue by End Markets- Academia and Government' of $141.26 million. The estimate points to a change of -3.3% from the year-ago quarter.
The consensus among analysts is that 'Revenue by End Markets- Diagnostics and Clinical' will reach $229.12 million. The estimate indicates a year-over-year change of -4.9%.
The average prediction of analysts places 'Revenue by End Markets- Chemical and advanced materials' at $358.04 million. The estimate indicates a year-over-year change of -5.3%.
Analysts' assessment points toward 'Net Revenue- Agilent Crosslab Group' reaching $410.12 million. The estimate indicates a change of +3.6% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue by End Markets- Environmental and Forensics' should come in at $157.49 million. The estimate indicates a change of -4% from the prior-year quarter.
Analysts forecast 'Net Revenue- Life Sciences and Applied Markets Group' to reach $754.65 million. The estimate suggests a change of -18.6% year over year.
The consensus estimate for 'Net Revenue- Diagnostics and Genomics Group' stands at $405.47 million. The estimate points to a change of +16.2% from the year-ago quarter.
Analysts expect 'Revenue by End Markets- Food' to come in at $135.66 million. The estimate indicates a change of -10.2% from the prior-year quarter.
Shares of Agilent have demonstrated returns of +6% over the past month compared to the Zacks S&P 500 composite's -1.5% change. With a Zacks Rank #4 (Sell), A is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Agilent (A) Q3 Earnings
Wall Street analysts expect Agilent Technologies (A - Free Report) to post quarterly earnings of $1.25 per share in its upcoming report, which indicates a year-over-year decline of 12.6%. Revenues are expected to be $1.56 billion, down 6.6% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 0.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
That said, let's delve into the average estimates of some Agilent metrics that Wall Street analysts commonly model and monitor.
Analysts predict that the 'Revenue by End Markets- Pharmaceutical' will reach $540.08 million. The estimate suggests a change of -8.8% year over year.
The collective assessment of analysts points to an estimated 'Revenue by End Markets- Academia and Government' of $141.26 million. The estimate points to a change of -3.3% from the year-ago quarter.
The consensus among analysts is that 'Revenue by End Markets- Diagnostics and Clinical' will reach $229.12 million. The estimate indicates a year-over-year change of -4.9%.
The average prediction of analysts places 'Revenue by End Markets- Chemical and advanced materials' at $358.04 million. The estimate indicates a year-over-year change of -5.3%.
Analysts' assessment points toward 'Net Revenue- Agilent Crosslab Group' reaching $410.12 million. The estimate indicates a change of +3.6% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenue by End Markets- Environmental and Forensics' should come in at $157.49 million. The estimate indicates a change of -4% from the prior-year quarter.
Analysts forecast 'Net Revenue- Life Sciences and Applied Markets Group' to reach $754.65 million. The estimate suggests a change of -18.6% year over year.
The consensus estimate for 'Net Revenue- Diagnostics and Genomics Group' stands at $405.47 million. The estimate points to a change of +16.2% from the year-ago quarter.
Analysts expect 'Revenue by End Markets- Food' to come in at $135.66 million. The estimate indicates a change of -10.2% from the prior-year quarter.
View all Key Company Metrics for Agilent here>>>
Shares of Agilent have demonstrated returns of +6% over the past month compared to the Zacks S&P 500 composite's -1.5% change. With a Zacks Rank #4 (Sell), A is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>